Department of Radiation Oncology, London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Department of Medical Biophysics, London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):582-589. doi: 10.1016/j.ijrobp.2018.12.044. Epub 2019 Jan 7.
Some recent studies have suggested a relationship between cardiac dose and mortality in non-small cell lung cancer (NSCLC), but others have reported conflicting data. The goal of this study was to conduct a systematic review and meta-analysis to provide an evidence-based estimate of the relationship between cardiac dose and mortality in these patients.
A systematic review of MEDLINE (PubMed) and Embase databases (inception to January 2018) was performed according to PRISMA guidelines. Studies that evaluated cardiac dosimetric factors in patients with NSCLC and included outcomes of cardiac events, cardiac mortality, and/or overall survival were identified.
From 5614 patients across 22 studies, a total of 214 cardiac dosimetric parameters (94 unique) were assessed as possible predictors of cardiac toxicity or death. Assessed predictors included general (eg, mean heart dose [MHD]), threshold-based (eg, heart V5), and anatomic-based (eg, atria, ventricles) dosimetric factors. The most commonly analyzed parameters were MHD, heart V5, and V30. Most studies did not make corrections for multiplicity of testing. For overall survival, V5 was found to be significant on multivariable analysis (MVA) in 1 of 11 studies and V30 in 2 of 12 studies; MHD was not significant in any of 8 studies. For cardiac events, V5 was found to be significant on multivariable analysis in 1 of 2 studies, V30 in 1 of 3 studies, and MHD in 2 of 4 studies. A meta-analysis of the data could not be performed because most negative studies did not report effect estimates.
Consistent heart dose-volume parameters associated with overall survival of patients with NSCLC were not identified. Multiplicity of testing is a major issue and likely inflates the overall risk of type I errors in the literature. Future studies should specify predictors a priori, correct for multiplicity of testing, and report effect estimates for nonsignificant variables.
一些最近的研究表明,非小细胞肺癌(NSCLC)中心脏剂量与死亡率之间存在关系,但其他研究则报告了相互矛盾的数据。本研究的目的是进行系统评价和荟萃分析,为这些患者中心脏剂量与死亡率之间的关系提供循证估计。
根据 PRISMA 指南,对 MEDLINE(PubMed)和 Embase 数据库(从创建到 2018 年 1 月)进行了系统评价。评估了 NSCLC 患者心脏剂量学因素并包括心脏事件、心脏死亡率和/或总生存结果的研究。
从 22 项研究的 5614 名患者中,共评估了 214 个心脏剂量学参数(94 个独特参数)作为心脏毒性或死亡的可能预测因子。评估的预测因子包括一般(例如,平均心脏剂量[MHD])、基于阈值(例如,心脏 V5)和基于解剖学(例如,心房、心室)的剂量学因素。分析最多的参数是 MHD、心脏 V5 和 V30。大多数研究没有对多重测试进行校正。对于总生存,在 11 项研究中的 1 项研究和 12 项研究中的 2 项研究中,V5 在多变量分析(MVA)中具有统计学意义;在 8 项研究中,MHD 均无统计学意义。对于心脏事件,在 2 项研究中的 1 项研究中,V5 在 3 项研究中的 1 项研究中,4 项研究中的 2 项研究中 MHD 在多变量分析中具有统计学意义。由于大多数阴性研究未报告效应估计值,因此无法对数据进行荟萃分析。
未确定与 NSCLC 患者总生存相关的一致心脏剂量-体积参数。多重测试是一个主要问题,可能会使文献中 I 型错误的整体风险增加。未来的研究应事先指定预测因子,对多重测试进行校正,并报告无统计学意义变量的效应估计值。